Introduction
Neisseria meningitidis is a leading cause of bacterial meningitis and septicemia in the developed world, where it can cause lifethreatening illness in individuals who lack the necessary protective antibodies, particularly children (Gidney et al. 2004 ). Attempts to produce a vaccine protective against N. meningitidis date to the 1970s and include studies of bacterial capsular polysaccharide and outer membrane proteins, with research on the lipooligosaccharide (LOS) beginning in the 1980s (Jennings et al. 1984; Vipond et al. 2012) . Vaccines against serogroups A, C, 135-W and Y of N. meningitidis have been available for years, and Bexsero ® , a vaccine targeting serogroup B, has recently been approved in some countries (Carter 2013) .
A bacterial capsular polysaccharide is composed mainly of repeating oligosaccharide units and surrounds the cell to shield the surface from immune surveillance. Vaccine initiatives targeting capsular polysaccharide have seen success in bacteria such as Haemophilus influenzae and certain strains of N. meningitidis (Borrelli et al. 2000; Andersen et al. 2002) ; however, the capsular polysaccharide of N. meningitidis serotype B consists mainly of α(2 → 8) linked polysialic acid, which is known to be poorly immunogenic as it mimics structures on host cell surfaces (Plested et al. 2001 (Plested et al. , 2003 Yang et al. 2012) . Inability to illicit an appropriate immune response using the capsular polysaccharide in serotype B has led to targeting the conserved inner core of LOS to overcome immune tolerance (Roberts 1996; Andersen et al. 2002; Gidney et al. 2004; Connor et al. 2006; Jäkel et al. 2008; Wenzel et al. 2010) .
Lipopolysaccharide (LPS) is a major surface component of Gram-negative bacteria and is usually composed of membraneanchored lipid A attached to a conserved oligosaccharide core followed by a repeating O-polysaccharide antigen. Non-enterobacteria in general lack the repeating O-polysaccharide antigen, and the lipid A-anchored core is commonly referred to as LOS (Borrelli et al. 2000; Jäkel et al. 2008; Wenzel et al. 2010) . Extension of the inner core in N. meningitidis at the β-D-glucose moiety (Glc) ( Figure 1A ) marks the beginning of the outer core.
Targeting the conserved inner core of LOS/LPS has been reported for an array of pathogenic bacteria, such as the human pathogens Escherichia coli (Di Padova et al. 1993 ), H. influenza (Borrelli et al. 2000) , Moraxella catarrhalis and Chlamydiaceae (Nguyen et al. 2003) , as well as veterinary pathogens Mannheimia haemolytica, Actinobacillus pleuropneumoniae and Pasteurella multocida (Borrelli et al. 2000; Logan et al. 2006; Cox et al. 2010 ). The conserved hexasaccharide that comprises the inner core of LOS from N. meningitidis is attached to lipid A via 3-deoxy-D-manno-oct-2-ulosonic acid residue (Kdo) residue I with extension to the outer core through Glc, Figure 1A (Gidney et al. 2004; Yang et al. 2012) . Significantly, LOS from N. meningitidis differs from that from other bacteria by a unique α(1 → 2) substitution of N-acetyl-Dglucosamine (GlcNAc) on L-glycero-D-manno-heptopyranose (Hep) residue II (Kabanov and Prokhorenko 2010; Yang et al. 2012) . Reported substitutions on this conserved inner core include β(1 → 2)Glc on HepI, phosphoethanolamine (PEtn) substitution at positions 3-OH and 6-OH on HepII and α(1 → 3) substitution of Glc on HepII ( Figure 1A ).
Polyclonal immune response to LOS inner core of N. meningitidis has been reported (Andersen et al. 2002; Jäkel et al. 2008) , with six murine monoclonal antibodies (mAbs) specific to the inner core of N. meningitidis subsequently cloned: LPT3-1, L4A4, L2-16, L5-10, L4-7 and L3B5 that displayed various specificities and activity to the inner core containing substitutions on HepII, summarized in Table I (Gidney et al. 2004) . Interestingly, of the six antibodies only mAb L3B5 was found to be protective. MAb L3B5 binds N. meningitidis LOS inner core only if HepII is PEtn monosubstituted at position 3-OH ( 70% of known serogroups) (Nguyen et al. 2003; Connor et al. 2006; St Michael et al. 2011) . MAb LPT3-1 provides partial protection and binds membrane-anchored LOS and can reduce bacteremia in the presence of a certain strain of N. meningitidis (Gidney et al. 2004 ). MAb LPT3-1 is more cross-reactive toward various inner core variants than L3B5 and recognizes the unsubstituted conserved inner core or the 3-OH or 6-OH PEtn monosubstituted HepII, but does not tolerate any other substitution or even the 3-OH, 6-OH PEtn disubstituted HepII variant.
Although the molecular basis for a particular antibody to display bactericidal or protective capability remains elusive (Nguyen et al. 2003; Connor et al. 2006; St Michael et al. 2011 ), Gidney et al. (2004 postulated that the relative level of protection offered by these antibodies could be due to factors such as accessibility of the inner core, affinity of the antibody for antigen or the stability of the induced membrane attack complex.
There are striking differences in functionality of the antibodies raised toward the inner core, and knowledge of the molecular structure of antibodies with different in vivo activity could provide insight into more effective vaccination targets. Only one structure of an antibody in complex with full-length inner core of LPS or LOS has been reported, and that is of mAb WN1 222-5 in complex with core R2 LPS from E. coli (Gomery et al. 2012) .
As a first step in investigating the biological activity and to develop our understanding of inner core immunogenicity and Selective cross-reactivity of an antibody against inner core LOS cross-reactivity of mAb LPT3-1, we have determined the structure of the antigen-binding fragment (Fab) of mAb LPT3-1 in complex with the unsubstituted inner core antigen from N. meningitidis to 2.69 Å resolution.
Results

Structure of LPT3-1 in complex with inner core antigen
The structure of the Fab of LPT3-1 was solved in complex with the eight-sugar inner core fragment NmL3 lpt3 KOH to 2.69 Å in space group P1. Data collection and refinement parameters are presented in Table II . Two molecules were observed in the asymmetric unit (AU), with clear density for the antigen in both combining sites. Omit (2Fo-Fc) maps surrounding the combining site of the Fab of LPT3-1 revealed electron density corresponding to five of the eight residues of the N. meningitidis inner core fragment ( Figure 1B ). No electron density was seen corresponding to the deacylated lipid A disaccharide backbone or for KdoII. Disordered regions were observed for both heavy chains from residues 129-132, inclusive. Overlap of the variable regions of the two molecules in the AU showed a root mean square deviation (RMSD) for all the 105 corresponding ordered α-carbon atoms of the light chain variable region and 112 corresponding ordered α-carbon atoms of the heavy chain variable region of 0.34 and 0.24 Å. The RMSD of the 67 corresponding atoms of the antigen was 0.61 Å, with a minimum of 0.07 Å and a maximum of 2.02 Å occurring for HepII-C1 and KdoI-O1A (a simple rotation of the carboxylate group), respectively. Upon respective overlap of the variable heavy and light chains, the RMSDs of α-carbon atoms for CDRs H1, H2 and H3 were 0.10, 0.22 and 0.13 Å with maximum of 0.14, 0.42 and 0.24 Å and minimum of 0.059, 0.074 and 0.046 Å, respectively. The RMSDs of α-carbon atoms for CDRs L1, L2 and L3 were 0.57, 0.23 and 0.14 Å with maximum of 1.27 (in ArgL31-note that the "H" or "L" in the residue name refers to the heavy and light antibody chains, respectively), 0.39 and 0.24 Å and minimum of 0.14, 0.093 and 0.084 Å, respectively.
Interactions between the antibody and antigen are mediated almost entirely through the heavy chain, with a total of nine hydrogen bonds (Table III, Figure 2A ). The epitope includes three sugars of the antigen, with all but one hydrogen bond occurring through the GlcNAc and HepII residues. The inner core antigen in both molecules in the AU retain all the nine hydrogen bonds and a single stacking interaction through the acetamido moiety with their respective combining sites, although the contact distances vary somewhat, Table III . This difference is most evident for ThrH56, which forms weak hydrogen bonds of 3.16 and 3.49 Å with Glc-O6 in the two molecules. The methyl group of the acetamido moiety of the GlcNAc residue lies in a hydrophobic groove between TyrH50 and TrpL91 only in contact with the former. A sulfate ion is observed in both combining sites hydrogen bonded to CDR H2, and in direct contact, with one antigen in the AU but not the other.
Germline gene analysis
The nucleotide sequence for Fab LPT3-1 was compared against the International Immunogenetics Information System (IMGT) database (Lefranc et al. 2009 ) for all known murine antibody sequences. LPT3-1 V-gene and J-gene were most closely related to IGHV5-17*02 F and IGHJ3*01 F genes with 97.92 Selective cross-reactivity of an antibody against inner core LOS and 100% identity, respectively. The light chain V-gene and J-gene were related to IGKV4-59*01 F and IGKJ5*01 F with 96.38 and 94.59% identity, respectively. The heavy chain exhibited seven mutations total, of which six were non-silent. Only two of the non-silent mutations are in the combining site (SH52G and SH52aG in CDR H2).
The light chain exhibited 11 mutations, of which nine were non-silent. A single (non-silent) mutation was found in CDR L1 and three in CDR L3. None of the mutations is positioned to influence antigen binding. All residues making contact with the antigen are of germline origin.
Discussion
The epitope is centered about the GlcNAc residue unique to N. meningitidis The epitope consists of the three sugars HepII, GlcNAc and Glc, which, respectively, form four, four and one hydrogen bonds to the protein surface ( Figures 1A and 2A , Table III) . A significant number of the hydrogen bonds are to the 3-OH, 4-OH and acetamido NH of the GlcNAc residue unique to N. meningitidis that, together with the contacts to HepII and Glc, provide the specificity to this unique LOS epitope. The importance of this trisaccharide moiety in antigen recognition is emphasized by its lower than average temperature factors and RMSD. Finally, the acetamido group of GlcNAc is projected into a hydrophobic groove where it forms a stacking interaction with TyrH50 with the methyl group packed against the aromatic ring center.
The hydrophobic faces of the HepII and GlcNAc rings are "back to back" with their 3-OH and 4-OH groups directed toward the surface of the heavy chain of Fab LPT3-1 to form a crooked "five-legged stool" together with the acetamido nitrogen atom of GlcNAc (Figure 2A ). These two sugar residues project from the inner core main chain of the LOS ( Figure 1A) , with the result that both the outer core that extends from the Glc residue and the lipid A that extends from KdoI are distal to the combining site. The accessible nature of the epitope is consistent with the facility with which mAb LPT3-1 binds membrane-anchored LOS (Gidney et al. 2004) .
The lack of observable density for the phosphorylated glucosamine disaccharide backbone and the location of its attachment point on KdoI well away from the antibody surface (Figure 1) show that the lipid A moiety does not form part of the epitope, nor does it serve to stabilize the antigen conformation. The 12.5 Å distance of the lipid A moiety from the antibody surface is consistent with the antibody's inability to distinguish between deacylated or acylated antigen (Gidney et al. 2004 ).
Mab LPT3-1's cross-reactivity toward PEtn variants stems from two mutations from germline One of the most interesting features of mAb LPT3-1 is its pattern of cross-reactivity with PEtn substituted HepII variants of the LOS core (Table I) . Approximately 76% of serogroup B strains and 70% of all strains of N. meningitidis display the 3-PEtn substitution on HepII (Gidney et al. 2004) . Interestingly, of the six monoclonal antibodies raised in response to the inner core LOS from N. meningitidis, only LPT3-1 and L3B5 recognize variants containing this moiety and only these two antibodies show any biological activity (Plested et al. 1999; Gidney et al. 2004 ). MAb L3B5 is protective, bactericidal and is specific to the 3-PEtn variant. In contrast, mAb LPT3-1 is partially protective, has some bactericidal activity, and will also cross-react with the unsubstituted core or the 6-PEtn truncated variant. MAb LPT3-1 will not cross-react with the 3,6-di-PEtn substituted variant or any 3-Glc substituted variant.
The basis for the ability of mAb LPT3-1 to bind the 6-PEtn substituted variant is apparent, as the 6-OH of HepII is accessible to the solvent and its substitution would pose no steric barrier to binding ( Figure 2A) ; however, the ability of mAb LPT3-1 to bind the 3-PEtn variant is remarkable given that the 3-OH group of the HepII forms two of the nine hydrogen bonds and lies at the heart of the antigen-antibody interface (Figure 2A and B) . Modeling the 3-PEtn variant shows that it could be accommodated in the combining site with modest movements of the side chain position of TyrH50 ( Figure 2B) .
Significantly, recognition of the 3-PEtn variant relies on two mutations from germline close to HepII. Two of six amino acid mutations from the germline heavy chain are in proximity to the species-specific trisaccharide core of the antigen, and only mutation to the smaller glycine at both SerH52 and SerH52a would allow binding of the 3-PEtn variant. Further, this means that the germline antibody is fully capable of binding the unsubstituted LOS from N. meningitidis without affinity maturation.
It is interesting to note that the corresponding germline antibody containing SerH52 and SerH52a would likely still bind the unsubstituted antigen, and probably do so with more interactions and greater avidity. The SH52G and SH52aG combining site mutations likely stem from the affinity maturation of LPT3-1 is a direct response to the 3-PEtn substitution on HepII found on >70% of N. meningitidis strains.
Finally, while the mechanism by which the extension of the outer core through the Glc residue abolishes binding of the HepII-6-PEtn variant (Table I) is not apparent in the current determination, it is consistent with the lack of cross-reactivity with the 3-Glc substitution on HepII as the substitution by the larger glucosyl residue in place of the smaller PEtn could not be accommodated by the combining site.
Comparison with mAb WN1 222-5 Although their primary structures are unrelated, mAb LPT3-1 shares characteristics with the only other published full-length inner core LPS/LOS antigen-antibody complex, Fab WN1 222-5 in complex with R2 core LPS from E. coli, which is specific to the conserved inner core of LPS from enterobacteria (Gomery et al. 2012) . First, both antibodies are cross-reactive to variants of the conserved LOS/LPS inner cores of their target bacteria. Secondly, the combining site contacts are dominated by germline residues, where there are two mutations from germline contacting the trisaccharide core of the antigen in mAb WN1 222-5, but none in mAb LPT3-1. Thirdly, both show heavy chain dominance in binding ( Figure 2C) ; mAb WN1 222-5 has one hydrogen bond out of 13 from the light chain and mAb LPT3-1 has none.
The combining sites in both mAbs LPT3-1 and WN1 222-5 are open grooves with a large proportion of the oligosaccharide exposed to solvent ( Figure 2C ), which contributes to observed cross-reactivity by allowing slight movement and minor substitutions in the antigens. For mAb WN1 222-5, the heavy chain contributes 478 Å 2 of buried accessible surface area versus 47.0 Å 2 for the light chain (Gomery et al. 2012) , which is similar in proportion to mAb LPT3-1 where the heavy chain contributes 273 versus 23.0 Å 2 for the light chain. Interestingly, the distinctive cross-reactivity properties displayed by the heavy chain dominant groove-type antibodies LPT3-1 and WN1 222-5 arise in part because the light chain does not sterically impede antigen binding and so select among the various inner core forms (Gomery et al. 2012) . The same level of heavy chain dominance displayed by WN1 222-5 and LPT3-1 has not been observed in other reported structures. More typical would be mAb F22-4 against the Shigella serotype 2a O-antigen at 345 and 262 Å 2 for the heavy and light chains, respectively (Vulliez-Le Normand et al. 2008) , and the anti-Le y mAb BR96 (Sheriff et al. 1996) at 370 and 158 Å 2 .
Selective cross-reactivity of mAb LPT3-1 Of the six mAbs reported by Gidney et al. that recognize in vitro the inner core of the LOS from N. meningitidis, only L3B5 was protective. MAb LPT3-1 did display partial protection by reducing bacteremia against both the 8047 lpt3 truncated unsubstituted LOS strain and the MC58 lpt3 galE truncated unsubstituted LOS strain (Gidney et al. 2004 ). MAb LPT3-1 produced a 2-log reduction in bacteremia for the 8047 lpt3, and was postulated to be partially protective in vivo (Gidney et al. 2004) . MAb L3B5 demonstrated protective capability against strains with truncated LOS (8047) and provided partial protection against strains with a mixture of truncated and un-truncated glycoforms (2996) displaying the 3-OH PEtn substitution (Plested et al. 1999) . The full protection offered by mAb L3B5 against the 3-OH PEtn substituted truncated inner core versus the partial protection offered by mAb LPT3-1 could be linked to the known ability of IgG3 to display molecular cooperativity in the formation of multivalent complexes (Greenspan and Cooper 1992) . MAb L3B5 is able to bind 70% of all N. meningitidis strains through specific recognition of the 3-PEtn substituted inner core. Through two mutations in the combining site, LPT3-1 is still specific to the inner core of N. meningitidis but recognizes a broader range of variants. Further investigation of the underlying mechanism by which the full-length LOS blocks LPT3-1 recognition of these three distinct variants of N. meningitidis is necessary to fully understand the functional immune response to the inner core.
Materials and methods
Production and sequencing of LPT3-1 LPT3-1 was produced as described in Gidney et al. 2004 . Sequencing was carried out by using the rapid amplification of cDNA ends (RACE) method as described in Bradbury 2010, with minor modifications. Amplification of the Fab region of mAb LPT3-1 (isotype IgG2a) was carried out with a set of degenerate primers. Briefly, total RNA was isolated from LPT3-1 hybridoma cells (circa 10 7 cells) using an RNeasy Midi Kit (Qiagen, Hilden, Germany) and served as template for cDNA synthesis. The first-strand of cDNA was synthesized with a primer specific to the hinge region of IgG2a (RACEMOG2a: 5′-AGG ACA GGG CTT GAT TGT GGG-3′) or with a primer specific to the 3′ end of the CL region (CKFOR: 5′-CTC ATT CCT GTT GAA GCT CTT GAC -3′) using the First-Strand cDNA Kit (GE Healthcare, Piscataway, NJ). The reactions were incubated at 42°C for 60 min and then at 52°C for 30 min as described in Bradbury 2010 and excess primers were removed with the MicroElute Cycle Pure Kit (Omega Bio-Tek, Norcross, GA). Subsequently, a poly-A tail was synthesized to the 5′ end of both cDNA reactions using recombinant terminal deoxynucleotidyl transferase (Promega, Madison, WI, USA). The RACE-ready cDNAs were amplified with the forward tag primer (XSCTnTag: 5′-GAC TCG AGT CGA CAT CGA TTT TTT TTT TTT TTT TT-3′) which annealed to the added 5′ end poly-A tail and with a reverse primer specific to the heavy chain (MOCG12FOR: 5′-CTC AAT TTT CTT GTC CAC CTT GGT GC) or the light chain (CKRAsp: 5′-CTC ATT CCT GTT GAA GCT CTT GAC GAC GGG-3′). The amplified variable and constant domain of the heavy chain and variable and constant domain of the light chain products were TA-cloned into the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA) and positive clones were sequenced with the universal M13 reverse primer (Invitrogen).
The sequence of the first 201 amino acids for the heavy chain and the first 204 amino acids of the light chain were determined, with the consensus for the IgG2aκ used to assign the identities of the remaining 19 and 10 residues, respectively.
Purification of LPT3-1
The intact IgG LPT3-1 was purified from ascites using a protein A/G column (Pierce, Rockford, IL) and digested into the Fab fragment with papain (Sigma-Aldrich, St Louis, IL). LPT3-1 was dialyzed into 20 mM N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES) (Sigma-Aldrich), pH 7.5, and diluted to 0.5 mg/mL with dithiothreitol (Sigma-Aldrich) and ethylenediaminetetraacetic acid (Sigma-Aldrich) at a final concentration of 5.0 and 2.0 mM, respectively. Digestion was accomplished by incubating papain to antibody in a 1:300 ratio for 4 h and quenched with 10 mM iodoacetamide (Sigma-Aldrich). The sample was dialyzed overnight in 20 mM HEPES (Sigma-Aldrich), pH 7.5, and the Fab subsequently purified with cation-exchange chromatography using a CM-825 column (Shodex, Tokyo, Japan) through the use of a linear gradient ranging from 0 to 0.5 M NaCl in 20 mM HEPES (Sigma-Aldrich), pH 7.5.
Crystallization of LPT3-1
Purified Fab of LPT3-1 was buffer exchanged into 20 mM HEPES (Biobasic, Markham, Canada), pH 7.5, and concentrated to 10.4 mg/mL. The Fab was incubated with 15 mM NmL3 galE lpt3 KOH and screened with Qiagen polyethylene glycols (PEGs) and PEGs II suites at a protein to reservoir ratio of 1:1. Small needle crystals ranging from 0.05 × 0.05 × 0.15 mm to 0.1 × 0.1 × 0.3 mm were observed in a variety of conditions of which E9 (0.2 M ammonium sulfate, 0.1 M HEPES, pH 7.5, 16% (w/v) PEG 4000, 10% (w/v) isopropanol) was optimized. Initial attempts to crystallize Fab LPT3-1 gave crystals with one long unit cell axis ( 250 Å) that resulted in a single incomplete data set to 3.2 Å resolution with an Rsym > 10% in Laue group 432 that could not be solved. Changing the ratio of protein to reservoir to 2:1 and extensive screening of drops led to the discovery of a second crystal type again in condition E9.
Data collection, structure determination and refinement Crystal fragments broken from crystals of the second crystal type were flash-frozen to −160°C using liquid nitrogen with Selective cross-reactivity of an antibody against inner core LOS mother liquor supplemented with 25% (v/v) glycerol (Anachemia, Montreal, Canada). All data were collected at the Canadian Light Source (Saskatoon, SK, Canada) using the Canadian Macromolecular Crystallography Facility at the 08ID-1 (CMCF-ID) beamline at a wavelength of 0.9795 Å. Molecular replacement using PHASER in the CCP4 suite (McCoy et al. 2007 ) was used to solve the structure of LPT3-1 using the structure of anti HIV1 protease Fab complex (PDB ID code 1MF2) as a search model. Manual fitting of σA-weighted Fo-Fc and 2Fo-Fc electron density maps was carried out with Coot (Emsley and Cowtan 2004) and SetoRibbon (Evans, unpublished) . Restrained refinement with REFMAC5 was implemented in CCP4 (Collaborative Computing Project 4 1994). Surface diagrams ( Figure 2C ) were prepared with PyMol (DeLano Scientific).
Residues have been numbered according to the Kabat convention (see http://www.bioinf.org.uk/abs/).
IMGT alignment
The International ImMunoGeneTics Information system (MariePaule Lefranc, Montpellierm France; www.imgt.org) (Ruiz et al. 2000; Lefranc et al. 2009 ) was used to compare murine BALB/c germline segments.
Kabat analysis
The sequence derived from the RACE method was analyzed by the UCL AbCheck and numbered according to the kabat scheme (Martin 1996) (http://www.bioinf.org.uk/abs/).
Buried accessible surface area calculation
The CCP4 program AREAIMOL (Lee and Richards 1971; Saff and Kuijlaars 1997) was used to calculate the accessible surface area of Fab LPT3-1 in contact with ligand.
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